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Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis
A Quantitative Coronary Angiography and Three-Dimensional
Intravascular Ultrasound Study
J. Eduardo Sousa, MD, PhD; Marco A. Costa, MD, PhD; Alexandre Abizaid, MD, PhD;
Amanda G.M.R. Sousa, MD, PhD; Fausto Feres, MD, PhD; Luiz A. Mattos, MD, PhD;
Marinella Centemero, MD; Galo Maldonado, MD; Andrea S. Abizaid, MD; Ibraim Pinto, MD;
Robert Falotico, PhD; Judith Jaeger, BA; Jeffrey J. Popma, MD; Patrick W. Serruys, MD, PhD
Background—We have previously reported the safety and effectiveness of sirolimus-eluting stents for the treatment of de
novo coronary lesions. The present investigation explored the potential of this technology to treat in-stent restenosis.
Methods and Results—Twenty-five patients with in-stent restenosis were successfully treated with the implantation of 1
or 2 sirolimus-eluting Bx VELOCITY stents in São Paulo, Brazil. Nine patients received 2 stents (1.4 stents per lesion).
Angiographic and volumetric intravascular ultrasound (IVUS) images were obtained after the procedure and at 4 and
12 months. All vessels were patent at the time of 12-month angiography. Angiographic late loss averaged 0.070.2 mm
in-stent and 0.050.3 mm in-lesion at 4 months, and 0.360.46 mm in-stent and 0.160.42 mm in-lesion after 12
months. No patient had in-stent or stent margin restenosis at 4 months, and only one patient developed in-stent restenosis
at 1-year follow-up. Intimal hyperplasia by 3-dimensional IVUS was 0.921.9 mm3 at 4 months and 2.554.9 mm3
after 1 year. Percent volume obstruction was 0.811.7% and 1.763.4% at the 4- and 12-month follow-up,
respectively. There was no evidence of stent malapposition either acutely or in the follow-up IVUS images, and there
were no deaths, stent thromboses, or repeat revascularizations.
Conclusion—This study demonstrates the safety and the potential utility of sirolimus-eluting Bx VELOCITY stents for the
treatment of in-stent restenosis. (Circulation. 2003;107:24-27.)
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Treating in-stent restenosis (ISR) has become one of themajor challenges for the interventional cardiologist.1
Regardless of which percutaneous approach is chosen to treat
an in-stent restenotic lesion (balloon angioplasty, stent, rota-
tional atherectomy, or laser angioplasty), 30% to 80% of the
patients will develop restenosis within the stent, at the stent
edges, or both. Currently, the only proven effective therapy
available for patients with ISR is intravascular brachythera-
py.2 Unfortunately, this complex therapy carries with it the
risks associated with ionizing radiation, including delayed
endothelialization and potential late vascular thrombosis.3
The first-in-man (FIM) study has recently demonstrated
the safety and effectiveness of sirolimus-eluting Bx VELOC-
ITY stents for the treatment of single, de novo coronary
lesions.4,5 In this somewhat benign population, no major
clinical events (thrombosis, repeat revascularization, myocar-
dial infarction, or death) occurred within 1-year of follow-up.
Twelve months after the index procedure, neointimal prolif-
eration and late lumen loss were virtually absent as deter-
mined both by quantitative intravascular ultrasound (IVUS)
and angiography. Subsequently, the multicenter RAndomized
study with the sirolimus-eluting Bx VELocity balloon-
expandable stent (RAVEL) study corroborated these results
by reporting the absence of restenosis 6 months after the
implantation of sirolimus-eluting stents in a similar subset of
patients with de novo, single vessel, coronary artery disease.6
Whether such unparalleled results would be replicated in a
more complex patient group, such as those with ISR, remains
to be determined.
The aims of this pilot study were to determine the feasi-
bility and safety of treating ISR with slow-release sirolimus-
eluting Bx VELOCITY stents and to determine the impact of
this technology on prevention of recurrent restenosis.
Methods
From March to June of 2001, 25 consecutive patients with ISR were
successfully treated with the implantation of the sirolimus-eluting Bx
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VELOCITY stent. Stents were coated with 140 g sirolimus/cm2 per
unit of metal surface area. The slow release formulation (28-day
drug release) was used in this protocol.4,5 Patients were excluded if
they had undergone previous intravascular radiation therapy to the
target vessel, if the index lesion was 36 mm in length, or if the
lesion was located in a saphenous vein graft.
Procedure
All stents were 18 mm long and varied from 2.5 to 3.5 mm in
diameter. There was no ostial lesion treated in the present investi-
gation. After predilatation of the target lesion, stents were deployed
with high-pressure (14 atmospheres) postdilatation, guided by
IVUS to assure complete stent expansion, which was defined as
in-stent minimal lumen area 80% of reference lumen area, and
apposition. Debulking devices were not used, and predilatation was
performed with conventional balloon. The operator was allowed to
implant up to 2 sirolimus-eluting stents to cover the entire length of
the lesion, but coverage of the entire stented segment was not
mandatory. Overlapping of the 2 adjacent sirolimus-eluting stents
was recommended per the protocol. All patients received aspirin
(325 mg/d, indefinitely) commencing at least 12 hours before the
procedure and clopidogrel 300 mg immediately after stent implan-
tation and 75 mg/d for 60 days thereafter. The protocol was approved
by the Medical Ethical Committee and informed consent was
obtained for every patient.
Quantitative Measurements
Postprocedure and 4- and 12-month quantitative coronary angiogra-
phy (QCA) and IVUS imaging were performed in all patients. IVUS
images were acquired using a motorized pullback at a constant speed
of 0.5 mm/sec and volumetric quantification was performed. Quan-
titative angiographic and volumetric IVUS analyses were performed
by independent Core laboratories (Brigham and Women’s Hospital,
Boston, Mass and Cardialysis B.V, Rotterdam, The Netherlands,
respectively). The three segments selected for volumetric IVUS
analysis were the segment covered by sirolimus-eluting stents and 2
edge segments (axially 5 mm proximal and distal to the sirolimus-
eluting stent margins). The presence of intimal hyperplasia in
previously deployed stents and anatomical landmarks noted by
angiography during stent deployment were used to guide IVUS
selection of the segment covered by sirolimus-eluting stents.
As described previously,5 2 coronary segments were subjected to
quantitative angiography, in-stent and in-lesion segments. The in-
stent analysis encompassed only the segment covered by sirolimus-
eluting stent. The in-lesion segment was defined as the in-stent
segment plus segments 5-mm proximal and 5-mm distal to the edge
or the nearest side branch if the side branch was nearer than 5 mm
from the stent edge. Contrast injection and angiography was per-
formed after positioning the stent delivery system just before
deployment. The relation between anatomic landmarks, including
the previously deployed stents, and the 2 radiopaque markers of the
delivery system were noted. In-stent and in-lesion restenosis were
defined as50% diameter stenosis (DS) at follow-up, located within
the stent and target lesion, respectively. Minimal lumen diameter
(MLD) and %DS were measured for each segment. In-lesion and
in-stent late lumen loss (LL) were calculated as postprocedure MLD
minus follow-up MLD. Validation of volumetric IVUS quantifica-
tion has been described elsewhere.7
Statistical Analysis
Continuous variables are expressed as meanSD. Comparisons
between postintervention and follow-up measurements were per-
formed with a 2-tailed paired t test. A probability value 0.05 was
considered statistically significant.
Results
The mean age was 5612 years; 80% of the patients were
male, and 24% were diabetics. Five patients (20%) had
recurrent ISR. The time interval between initial bare metal
stent implantation and development of in-stent restenosis
varied from 3 to 7 months. Lesions were classified as focal
(10 mm) in 32%, diffuse intrastent in 40%, and diffuse
proliferative in 28% of the patients according to previously
reported classification.1 All stents were implanted success-
fully. Stent edge dissection was not detected either by
angiography or IVUS and patients were discharged without
complications 24 hours after treatment.
All patients were free of angina after 1 year, and there were
no repeat revascularizations, stent thromboses, or major
adverse clinical events (cerebrovascular accident, myocardial
infarction, or death) during this time.
Angiographic data are presented in Table 1. At 4
months, in-stent lumen diameter remained essentially un-
changed from postprocedure in 50% of the cases (Figure
1). Minimal angiography lumen gain observed in some
patients may be explained by regression of intimal hyper-
plasia that was not covered with the sirolimus-eluting
stent. There was a slightly but statistically significant
decrease in in-stent MLD between 4 and 12 months (Table
1, Figure 1), whereas in-lesion MLD was essentially
unchanged after 12 months (Table 1, Figure 1). Only 1
patient, who was asymptomatic, developed in-stent reste-
TABLE 1. Quantitative Coronary Angiographic Analysis
Parameters Preprocedure Postprocedure 4-Month Follow-Up 12-Month Follow-Up
RD, mm 2.780.3 2.80.4 2.840.3 2.80.3
MLD, mm 1.050.3         
DS, % 62.210.5         
Lesion length, mm 13.67.65         
In-stent MLD, mm    2.710.3 2.640.4 2.350.6*
In-lesion MLD, mm    2.340.4 2.390.4 2.180.6†
In-stent DS, %    2.69 7.158.57 16.717.7
In-lesion DS, %    16.58.2 15.969.1 22.916.9
In-stent late loss, mm       0.070.2 0.360.46
In-lesion late loss, mm       0.050.3 0.160.42
RD indicates reference diameter.
*P0.001 for in-stent MLD postprocedure versus 12-month follow-up.
†P0.001 for in-stent late loss 4-month versus 12-month follow-up.
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nosis at 12 months. IVUS imaging was not performed in
this patient. IVUS analysis showed minimal neointimal
hyperplasia volume (0.921.9 mm3 at 4 months and
2.554.9 mm3 at 12 months) in the remaining patients
(Table 2).
Discussion
The present study demonstrates the feasibility of using
sirolimus-eluting stents for the treatment of ISR. All patients
were asymptomatic, and only 1 patient developed in-stent
restenosis 12 months after treatment. In-stent intimal hyper-
plasia was minimal in most patients (Figure 2), and the
in-lesion late loss was only 0.16-mm. Most importantly, the
12-month clinical follow-up was uneventful for all patients.
A number of clinical studies have documented the chal-
lenge of treating ISR because of the high recurrence of
restenosis (30% to 80%),1,8 which is directly related to the
length of the ISR lesion and independent of device selection.
Only recently has catheter-based intravascular brachytherapy
become available as an effective treatment for patients with
ISR.2 Although intravascular brachytherapy trials have con-
sistently shown a 40% to 70% reduction in re-restenosis as
compared with placebo, there is still a 17% to 32% long-term
failure rate for patients treated with brachytherapy.2,9,10 The
pioneer Scripps Coronary Radiation to Inhibit Proliferation
Post Stenting (SCRIPPS) study irradiated 26 patients (62%
had ISR) using the Iridium-192 gamma-source.2 Lesion
length was 10 mm in 42% of the patients. Out of the 24
patients with complete angiographic follow-up, 17% had
recurrent restenosis.
In the present study, in which 68% of the patients had
diffuse ISR, there was no in-stent or edge restenosis 4 months
after the implantation of sirolimus-eluting stents, and only 1
patient developed restenosis at 12 months. This patient had a
Figure 1. Cumulative distribution curves
of angiographic in-stent (IS, upper panel)
and in-lesion (IL, lower panel) minimal
lumen diameter (MLD) after the proce-
dure (Post) and at 4-month and
12-month follow-ups.
TABLE 2. Quantitative Intravascular Ultrasound Analysis
Parameters Postprocedure 4-Month Follow-Up 12-Month Follow-Up*
Stented segment length, mm 21.67.4 21.67.5 21.97.34
Mean lumen area, mm2 6.741.82 6.811.9 7.061.81
Percent obstruction volume, %    0.811.7 1.763.44
Peri-stent margins
Distal mean lumen area, mm2 7.042.5 7.272.7 7.242.43
Proximal mean lumen area, mm2 7.462.39 82.78 82.59
Distal mean total vessel area, mm2 12.645.16 12.694.94 12.995.15
Proximal mean total vessel area, mm2 15.353.85 15.994.11 15.544.29
*Data do not include 1 patient with in-stent restenosis in whom the lesion could not be crossed with the IVUS
catheter.
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saphenous vein graft to the right coronary artery, and the 80%
DS repeat ISR was located in the native artery distally to the
site of graft anastomosis. Whether the proximity of the vein
graft influenced the angiographic outcome remains to be
clarified. The average change in MLD between 4 and 12
months shown by QCA was largely driven by this and one
other patient who showed additional late loss (Figure 1),
rather than by a systematic increase in late loss in all 25
patients.
Although clopidogrel was given for only 60 days after the
procedure, there were no silent or overt stent thromboses as
assessed by angiography and IVUS at 4 and 12 months,
which was a 10-month period off dual antiplatelet therapy.
This is also consistent with the observations in the RAVEL
study, where patients have been off dual antiplatelet agents
for at least 10 months without thrombotic events.6 This
should be compared with the 6% late thrombosis rate
observed after intracoronary radiation therapy,3 which re-
sulted in the recommendation for prolonged antiplatelet
therapy (6 to 12 months) after brachytherapy, especially when
a new stent is implanted at the time of the procedure. The
outcomes of patients with ISR treated with stents covered
with a polymer containing a paclitaxel derivative have been
reported recently.11 Although the results seemed promising
after 6 months, 8 out of 13 patients had restenosis at 12
months and 2 patients experienced non–Q-wave myocardial
infarctions due to stent occlusion.11
The lack of a control group clearly precludes a definitive
scientific assessment of the excellent outcomes observed in
the present study. The lack of stent thrombosis, repeat
revascularization, myocardial infarction, or death in this
patient population, however, indicates that the antiprolifera-
tive and antiinflammatory actions of sirolimus12 may provide
a long-lasting antirestenosis effects after treatment of ISR
lesions without the attendant risk of stent thrombosis ob-
served with other effective treatment modalities. Longer-term
follow-up will be required to determine whether the inhibi-
tion of in-stent restenosis observed in this study is sustained.
Although these data in a small cohort of patients are very
encouraging, randomized controlled trials will be necessary
to determine whether the reduction in late lumen loss,
restenosis, and need for repeat intervention is indeed better
than with brachytherapy, is sustained over several years, and
can be achieved without the need for extended antiplatelet
therapy.
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Figure 2. Preprocedure, postprocedure, 4-month, and 12-month
follow-up angiography of a right coronary diffuse ISR lesion
treated with 2 sirolimus-eluting stents. Lumen dimensions
remained unchanged at 4-month and 12-month follow-up
(bottom).
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